Engineered immune cells for KRAS-mutated advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of solid tumor that cannot be removed surgically or has spread, and standard treatments no longer work or you cannot tolerate them.
- You have a specific genetic marker called HLA-A*11:01 and your tumor has a KRAS G12V or G12D mutation.
- Your cancer can be measured on scans (at least one measurable lesion).
- You are in generally good health (able to do most daily activities) and your organs are working well enough for the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This Phase 1 trial tests an engineered immune cell treatment (“T cells”) made to recognize a specific tumor change (KRAS G12V) in people with advanced solid tumors. It’s intended for cancers that did not respond to standard treatments, and the goal is to see safety and early signs of benefit.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.